<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Eli Lilly and Company (LLY) on Thursday reported positive topline results from the Phase III TRIUMPH-1 trial evaluating Retatrutide in adults with obesity or overweight, at least one weight-related comorbidity, and without diabetes.</p><p>At 80 weeks, all doses of retatrutide met the trial's primary and key secondary endpoints, delivering significant weight loss. Participants receiving the 9 mg and 12 mg doses lost an average of 64.4 pounds, or 25.9%, and 70.3 pounds, or 28.3%, respectively. Patients taking the 4 mg dose lost an average of 47.2 pounds, or 19.0%.</p><p>Among participants taking the 12 mg dose, 65.3% achieved a body mass index below 30 at week 80, moving below the obesity threshold. This included 37.5% of patients who entered the trial with class 3 obesity, defined as a BMI of 40 or higher.</p><p>In an extension study involving participants with a BMI of at least 35, those continuing treatment with retatrutide 12 mg through 104 weeks lost an average of 85 pounds, or 30.3%.</p><p>The drug candidate also demonstrated improvements in several cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein levels.</p><p>Lilly shares closed at $1,018.87 on Wednesday, down 0.25%. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

ELIS

ELIL

LABU

<p>Eli Lilly reported positive results from the Phase III TRIUMPH-1 trial for Retatrutide, showing significant weight loss in adults with obesity. At 80 weeks, participants lost an average of 64.4 pounds (25.9%) on the 9 mg dose and 70.3 pounds (28.3%) on the 12 mg dose. Additionally, 65.3% of those on the 12 mg dose achieved a BMI below 30. The drug also improved cardiovascular risk factors. Lilly shares closed at $1,018.87, down 0.25%.</p>

Lilly Reports Positive Topline Data From Phase III Obesity Study Of Retatrutide